Severe Asthma Update: Clinical Management and Key Considerations to Target Optimal Patient Care – 9/26

Join us NOW for a social media livestream event!  

September 26, 2020
10:00 AM – 10:45 AM EDT




Stanley M. Fineman, MD, MBA
Adjunct Associate Professor of Pediatrics
Emory University School of Medicine
Atlanta Allergy & Asthma
Atlanta, Georgia


Reynold A. Panettieri, Jr, MD
Professor of Medicine
Robert Wood Johnson Medical School
Vice Chancellor, Clinical & Translational Science
Director, Rutgers Institute for Translational Medicine & Science
New Brunswick, New Jersey
Emeritus Professor of Medicine
University of Pennsylvania
Philadelphia, Pennsylvania


Patients with severe asthma suffer frequent exacerbations and unpredictability of their disease. Prior to the availability of newer therapies that provide an opportunity to improve the management of patients with severe asthma, many patients relied on oral corticosteroids (OCS) as a mainstay of treatment. The utility of new therapies is underscored by the need for clinicians to be competent in making an efficient and accurate diagnosis and classification of severe asthma, to possess knowledge of recently released guidelines for severe asthma management, and to be able to select appropriate individualized therapy based on patient profiles and desires. The goal of this program is to ensure that clinicians are able to meet the needs of the diverse population of severe asthma patients, to design effective treatment plans that reduce symptoms and exacerbations and address the continued need for OCS in patients with severe asthma, and to recognize and treat common and rare comorbidities that present with severe asthma. Furthermore, this program will address specific considerations arising as a result of the COVID-19 pandemic and its potential detrimental impact on patients with severe asthma.


This educational initiative has been designed for allergists, pulmonologists, internal medicine clinicians, and advanced practice providers involved in the management of patients with severe asthma.


Upon completion of this educational activity, participants should be able to:

  • Apply available guidance to diagnose patients with severe versus difficult-to-treat versus persistent uncontrolled asthma
  • Identify biomarkers that define types of severe asthma and utilize results to classify patients with severe asthma
  • Develop personalized treatment plans for patients with severe asthma that are consistent with current evidence-based recommendations
  • Identify comorbidities that have an impact on the treatment of severe asthma and discuss treatment strategies
  • Describe prevention and treatment strategies for patients with severe asthma exposed to coronavirus or diagnosed with COVID-19


There is no registration fee for participating in this activity. To register, click the registration buttons on this page or call Integrity Continuing Education, Inc. at 1-855-835-4004.


Accreditation Statement
Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation
Integrity Continuing Education, Inc. designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


Accreditation Statement

Global Education Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Credit Designation
Global Education Group designates this continuing education activity for 1.0 contact hours (0.10 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Numbers – 0530-9999-20-097-L01-P)

This is a knowledge-based activity.


Global Education Group is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

This educational activity for 1.0 contact hours is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.


For information about the ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or

For information about the ACPE or ANCC accreditation of this activity, please contact Global Education Group at (303) 395-1782 or


Integrity Continuing Education, Inc. and Global Education Group require instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Stanley M. Fineman, MD, MBA
Consulting Fees: Aimune, Biocryst, DBV, Regeneron
Speakers’ Bureaus: Takeda

Reynold A. Panettieri, Jr, MD
Consulting Fees: AstraZeneca, Equillium, MedImmune, RIFM, Theravance
Contracted Research: AstraZeneca, Genentech, MedImmune, OncoArendi, RIFM
Speakers’ Bureaus: AstraZeneca, Genentech, Sanofi

The Integrity Continuing Education, Inc. planners/mangers and the Global Education Group planners/managers, Ashley Marostica, RN, MSN, Lindsay Borvansky, Andrea Funk, Liddy Knight, and Ashley Cann, have nothing to disclose.


This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. and Global Education Group do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the view of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


In order to participate, learners must have an internet connection strong enough to support the viewing of live video via social media.


The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient’s medical condition.


This CME activity is provided by Integrity Continuing Education, Inc.

This CEU/CNE activity is jointly provided by Global Education Group and Integrity Continuing Education, Inc.

Supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.



Prior to the program, please take the following pretest:

On the day of the program, you may access the event by going to any of the following links:


There are no fees for participating and receiving CME credit for this activity. For your participation you will be able to receive a maximum of 1.0 AMA PRA Category 1 CME credit(s). To do so, you must participate in the virtual live stream activity and complete the posttest and evaluation following the event. A statement of credit will be issued only upon submission of a completed activity evaluation form. For pharmacists/ACPE learners, please check the CPE monitor for your CE credit within 60 days of the activity.